Nitrogen Bonded Directly To Phenothiazine Ring System Patents (Class 544/37)
-
Publication number: 20120328530Abstract: A compound of formula (III), or a pharmaceutically acceptable derivative thereof for use in a method of combating and/or detecting a pathogen and/or tumour cells; wherein X is selected from O, S and Se; each of R2, R3 and R4 is independently selected from hydrogen or an optionally substituted alkyl, alkenyl, alkynyl or aryl group; and R1 is selected from halogen, sulfo, acyl, sulfoxy, mercapto, nitro, amino, hydroxy or an optionally substituted alkyl, alkenyl, alkynyl, aryl, amine or alkoxy group; wherein R1 is not methyl or hydrogen when each of R3 and R4 is methyl or hydrogen.Type: ApplicationFiled: March 11, 2011Publication date: December 27, 2012Applicant: PHARMALUCIA LIMITEDInventor: Mark Wainwright
-
Publication number: 20120302556Abstract: Compounds and methods for preventing and treating viral infections are provided. In some embodiments, novel compounds broad-spectrum antiviral activity are provided. In more specific embodiments, the compounds and methods are effective against viruses such as Venezuelan Equine Encephalitis, West Nile Virus, and Hepatitis C.Type: ApplicationFiled: March 29, 2012Publication date: November 29, 2012Applicant: PROSETTA ANTIVIRAL INC.Inventors: Clarence R. Hurt, Vishwanath Lingappa, Beverly Freeman, Andy Atuegbu, Anatoliy Kitaygorodskyy
-
Publication number: 20120289499Abstract: Substantially pure methylthioninium chloride pentahydrate form A is prepared from methylthioninium chloride by phase equilibration of suspensions, crystallization or solvent evaporation, whereby the water content of the solvent corresponds to a water activity of at least 0.4 at 25° C., and controlled drying of said methylthioninium chloride pentahydrate form A within its stability ranges of humidity, pressure and temperature.Type: ApplicationFiled: September 23, 2010Publication date: November 15, 2012Inventors: Rolf Hilfiker, Timo Rager
-
Publication number: 20120270854Abstract: Compounds and methods for preventing and treating viral infections are provided. In some embodiments, novel compounds broad-spectrum antiviral activity are provided. In more specific embodiments, the compounds and methods are effective against viruses such as Venezuelan Equine Encephalitis, West Nile Virus, and Hepatitis C.Type: ApplicationFiled: April 20, 2012Publication date: October 25, 2012Applicant: PROSETTA ANTIVIRAL INC.Inventors: Clarence Hurt, Vishwanath Lingappa, Beverly Freeman, Anatolly Kitaygorodskyy, Andy Atuegbu
-
Patent number: 8283347Abstract: A non-leaching mediator may include a compound having the general formula (I): and salts thereof, where n is about 9, and X is a halogen; a compound having the general formula (II): and salts thereof, where n is about 9, and X is a halogen; and/or a compound, having the general formula (III): and salts thereof, where n is about 8, and X is a halogen.Type: GrantFiled: May 28, 2010Date of Patent: October 9, 2012Assignee: Bayer HealthCare LLCInventors: Jiangfeng Fei, William Chiang, Frank Kerrigan, Stuart Green
-
Publication number: 20120238556Abstract: Three dihydrate forms B, C and D and a monohydrate form E of methylthioninium chloride are described. Forms B, C, D and E can be prepared under controlled humidity and temperature from methylthioninium chloride with higher water content or conversion of a hydrate. The hydrates can be incorporated in pharmaceutical compositions.Type: ApplicationFiled: September 23, 2010Publication date: September 20, 2012Inventors: Rolf Hilfiker, Timo Rager
-
Publication number: 20120238543Abstract: Novel compounds, methods, and compositions for treating various viral infections are described. In some embodiments the novel compounds of the invention are 3-oxo-phenothiazine derivatives; more specific embodiments include 3-oxo-phenothiazine derivatives having substituents at the 1-, 7-, and 9-positions of the phenothiazine parent ring. In other embodiments, the invention provides compositions and methods for treating viral infections, especially HIV.Type: ApplicationFiled: March 16, 2012Publication date: September 20, 2012Applicant: Prosetta Antiviral, Inc.Inventors: Clarence Hurt, Beverly Freeman, Vishwanath Lingappa, Andy Atuegbu, Anatoliy Kitaygorodskyy
-
Publication number: 20120157435Abstract: Compounds and methods for preventing and treating viral infections are provided. In some embodiments, novel compounds broad-spectrum antiviral activity are provided. In more specific embodiments, the compounds and methods are effective against viruses such as Venezuelan Equine Encephalitis, West Nile Virus, and respiratory viruses including the common cold.Type: ApplicationFiled: May 2, 2011Publication date: June 21, 2012Applicant: PROSETTA ANTIVIRAL INC.Inventors: Clarence Hurt, Beverly Freeman, Vishwanath Lingappa, Andy Atuegbu, Anatoliy Kitaygorodorskyy
-
Publication number: 20120014858Abstract: A method of preparing hydrophobic silica particles includes the step of reacting together in a single step a mixture of silane ether monomers and organically modified silane ether monomers with a hydrolyzing agent. The method also includes producing hydrophobic silica microparticles and nanoparticles that can include dyes and/or magnetizable components. The silica nanoparticles can be used in the detection, visualization and/or analysis of latent fingerprints.Type: ApplicationFiled: September 26, 2011Publication date: January 19, 2012Inventor: Frederick John Rowell
-
Publication number: 20120013246Abstract: A dendrimer and an organic light-emitting device including an organic layer having the dendrimer.Type: ApplicationFiled: July 8, 2011Publication date: January 19, 2012Applicant: Samsung Mobile Display Co., Ltd.Inventors: Yoon-Hyun KWAK, Jeoung-In Yi, Seung-Gak Yang, Hee-Yeon Kim, Jae-Yong Lee
-
MATERIAL FOR PHOSPHORESCENT LIGHT-EMITTING ELEMENT AND ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME
Publication number: 20120001165Abstract: Provided is an organic electroluminescent device (organic EL device), which has improved luminous efficiency, has sufficient driving stability, and has a simple construction. The organic EL device of the present invention is an organic electroluminescent device, including a light-emitting layer and a hole-transporting layer between an anode and a cathode laminated on a substrate, in which the light-emitting layer contains a phosphorescent light-emitting dopant and an indolocarbazole compound that serves as a host material, or alternatively, the hole-transporting layer contains an indolocarbazole compound. The indolocarbazole compound is represented by the following formula (1). In the formula: A1's each represent an aromatic hydrocarbon group or an aromatic heterocyclic group, provided that at least one of A1's has a fused ring structure; and R1's each represent a hydrogen atom, an alkyl group, an alkoxy group, or an acyl group.Type: ApplicationFiled: March 25, 2010Publication date: January 5, 2012Inventors: Masaki Komori, Takahiro Kai, Toshihiro Yamamoto -
Publication number: 20120003746Abstract: Field test kits for detecting explosive substances including a combination of reagents for sequentially testing for perchlorates, nitro aromatic compounds, nitroamines, nitroesters, chlorates, bromates, peroxides and nitrates are discussed. The reagents in the kits may contain methylene blue, methylene blue in a basic solution, and an acidified aromatic amine solution. Methods for employing the test kits are discussed, the methods being suitably adapted to detect the moieties suspected of being present. The kits may include a reagent for detecting explosive perchlorates, the reagent being methylene blue. The kits also include a reagent for detecting explosive nitroamines and nitroesters, the reagent being an acidified aromatic amine solution. The aromatic amine solution also can detect nitro aromatic explosives after a strong basic hydroxide has first been applied to the suspected substance.Type: ApplicationFiled: February 1, 2010Publication date: January 5, 2012Applicant: MISTRAL DETECTION LTD.Inventor: Shai Amisar
-
Publication number: 20110306576Abstract: A compound of formula (II) or a pharmaceutically acceptable derivative thereof for use in a method of combating and/or detecting a pathogen; wherein X is selected from O, S and Se; each of R1, R2, R4, R6, R8, R9, R11, R12, R13 and R14 is independently selected from hydrogen, halogen, sulfo, sulfoxy, mercapto, acyl, nitro, amino or an optionally substituted alkyl, alkenyl, alkynyl, aryl, amine or alkoxy group; provided that at least one of R11, R12, R13 and R14 is an optionally substituted amine group.Type: ApplicationFiled: February 25, 2010Publication date: December 15, 2011Applicant: PHARMALUCIA LIMITEDInventor: Mark Wainwright
-
Publication number: 20110294795Abstract: Described are compositions and methods of making high purity diaminophenothiazinium compounds of the following formula which are characterised by: a purity of greater than 98%; less than 1% Azure B as impurity; less than 0.15% Azure A as impurity; less than 0.15% Azure C as impurity; and less than 0.05% Methylene Violet Bernthsen (MVB) as impurity. Examples include methylthioninium chloride (MTC), also known as Methylene Blue (MB).Type: ApplicationFiled: May 31, 2011Publication date: December 1, 2011Inventors: Claude Michel WISCHIK, John Mervyn David Storey, Colin Marshall, James Peter Sinclair, Thomas Craven Baddeley
-
Patent number: 8022204Abstract: A method of forming a 3-phenylimino-3H-phenothiazine or a 3-phenylimino-3H-phenoxazine mediator includes providing a first reactant including phenothiazine or phenoxazine, providing a first solvent, providing a second reactant and providing a second solvent. The first reactant, first solvent, second reactant and second solvent are combined to form a reactants solution. Sodium persulfate is added to the reactants solution to couple the first and second reactants resulting in a reaction solution including the 3-phenylimino-3H-phenothiazine or the 3-phenylimino-3H-phenoxazine mediator.Type: GrantFiled: December 9, 2008Date of Patent: September 20, 2011Assignee: Bayer Healthcare LLCInventors: Karen L. Marfurt, Henry C. Arndt
-
Publication number: 20110190480Abstract: The present invention relates to dyes of the general formula CAT+ Y? (I), where Y? is an anion selected from the group of the cyanoborates, fluoroalkylphosphates, fluoroalkylborates or imidates and CAT+ is a cation selected from the group of the azine, xanthene, polymethine, styryl, azo, tetrazolium, pyrylium, benzopyrylium, thiopyrylium, benzothiopyrylium, thiazine, oxazine, triarylmethane, diarylmethane, methine, acridine, quinoline, isoquinoline or quaternary azafluorenone dyes, for colouring plastics and plastic fibres, for the preparation of flexographic printing inks, as ball-point pen pastes, as stamp ink, for colouring leather and paper, for use in data acquisition systems, reprography, in ink microfilters, in photogalvanics, laser technology and the photo industry.Type: ApplicationFiled: April 11, 2011Publication date: August 4, 2011Inventors: Nikolai (Mykola) IGNATYEV, Urs Welz-Biermann, Helge Willner, Maik Finze, Eduard Bernhardt, Andriy Kucheryna
-
Publication number: 20110178071Abstract: Compounds and methods for preventing and treating viral infections are provided. In some embodiments, novel compounds broad-spectrum antiviral activity are provided. In more specific embodiments, the compounds and methods are effective against viruses such as Venezuelan Equine Encephalitis, West Nile Virus, and Hepatitis C.Type: ApplicationFiled: April 3, 2008Publication date: July 21, 2011Inventors: Jacob Plattner, Colm Kelleher, Vishwanath Lingappa, Beverly Freeman, William Hansen
-
Patent number: 7956183Abstract: A method for the synthesis of a diaminophenothiazinium compound of the following formula: comprising (a) purifying a corresponding reduced compound which is N-acylated at the heterocyclic nitrogen; (b) deacylating the purified compound to provide the corresponding reduced compound; and (c) oxidizing the reduced compound to provide the diaminophenothiazinium compound. Optional purification may performed, for example, after deacylating and after oxidizing. The method provides high purity diaminophenothiazinium compounds which are suitable for pharmaceutical and related therapeutic uses. Such uses include inactivating pathogens, the treatment of the infectious diseases, and for the treatment of diseases of protein aggregation, such as tauopathies, including Alzheimer's disease.Type: GrantFiled: July 10, 2007Date of Patent: June 7, 2011Assignee: WisTa Laboratories Ltd.Inventors: Claude Michel Wischik, John Mervyn David Storey, Colin Marshall, James Peter Sinclair, Thomas Craven Baddeley
-
Patent number: 7906643Abstract: A methylene blue-curcumin hybrid useful in treating Alzheimer's Disease.Type: GrantFiled: February 1, 2010Date of Patent: March 15, 2011Assignee: Codman & Shurtleff, Inc.Inventor: Thomas M DiMauro
-
Patent number: 7888350Abstract: This invention pertains generally to the field of phenothiazine compounds, and more particularly to certain stably reduced phenothiazine compounds, specifically, certain 3,7 diamino-10H-phenothiazine (DAPTZ) compounds of the following formula wherein: each of R1 and R9 is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R3NA and R3NB is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R7NA and R7NB is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of HX1 and HX2 is independently a protic acid; and pharmaceutically acceptable salts, solvates, and hydrates thereof. These compounds are useful as drugs, for example, in the treatment of tauopathies, such as Alzheimer's disease, and also as prodrugs for the corresponding oxidized thioninium drugs (for example, methythioninium chloride, MTC).Type: GrantFiled: March 28, 2007Date of Patent: February 15, 2011Assignee: Wista Laboratories Ltd.Inventors: Claude Michel Wischik, Janet Elizabeth Rickard, Charles Robert Harrington, David Horsley, John Mervyn David Storey, Colin Marshall, James Peter Sinclair, Thomas Craven Baddeley
-
Publication number: 20110034447Abstract: Disclosed is a transformed cell (a cell model) which can form a cytoplasmic inclusion body derived from TAR DNA-binding protein of 43 kDa (TDP-43) that is found in the brain of a patient suffering from a neurodegenerative disease such as FTLD and ALS. The transformed cell is characterized by having, introduced therein, a promoter capable of functioning in a host cell and a mutant TDP-43 gene.Type: ApplicationFiled: March 6, 2009Publication date: February 10, 2011Inventors: Takashi Nonaka, Tetsuaki Arai, Haruhiko Akiyama, Masato Hasegawa, Makiko Yamashita
-
Publication number: 20110021510Abstract: This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7 diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiaziniumcompounds”) including Methylhioninium Chloride (MTC) (also known as Methylene Blue). In one embodiment, the method comprises the steps of, in order: nitrosylation (NOS); nitrosyl reduction (NR); thiosulfonic acid formation (TSAF); oxidative coupling (OC); Cr(VI) reduction (CR); isolation and purification of zwitterionic intermediate (IAPOZI); ring closure (RC); chloride salt-formation (CSF); one of: sulphide treatment (ST); dimethyldithiocarbamate treatment (DT); carbonate treatment (CT); ethylenediaminetetraacetic acid treatment (EDTAT); organic extraction (OE); and recrystallisation (RX). The present invention also pertains to the resulting (high purity) compounds, compositions comprising them (e.g.Type: ApplicationFiled: September 3, 2010Publication date: January 27, 2011Inventors: John Mervyn David STOREY, James Peter SINCLAIR, Colin MARSHALL, Han Wan TAN, Claude Michel WISCHIK
-
Publication number: 20110015391Abstract: The present invention provides a stabilizer that can stabilize a salt of 10-(carboxymethylaminocarbonyn-3,7-bis(dimethylamino)phenothiazine or a derivative thereof even under the existence of moisture or under light irradiation. A compound described in at least one of (1) and (2) below is used as the stabilizer of the salt of 10-(carboxymethylaminocarbonyl)-3,7-bis(dimethylamino)phenothiazine or the derivative thereof.Type: ApplicationFiled: March 18, 2009Publication date: January 20, 2011Applicant: ARKRAY, INC.Inventors: Satoshi Yonehara, Norio Inamura
-
Publication number: 20100300896Abstract: A non-leaching mediator may include a compound having the general formula (I): and salts thereof, where n is about 9, and X is a halogen; a compound having the general formula (II): and salts thereof, where n is about 9, and X is a halogen; and/or a compound, having the general formula (III): and salts thereof, where n is about 8, and X is a halogen.Type: ApplicationFiled: May 28, 2010Publication date: December 2, 2010Applicant: BAYER HEALTHCARE LLCInventors: Jiangfeng Fei, William Chiang, Frank Kerrigan, Stuart Green
-
Publication number: 20100279850Abstract: A coating composition comprising a Photocatalyst Composition comprising a photocatalyst and a pendent silyl ester group, wherein the photocatalyst produces singlet oxygen in the presence of light and ambient air. In certain embodiments, the coating composition further comprises a singlet oxygen scavenger.Type: ApplicationFiled: January 5, 2010Publication date: November 4, 2010Inventors: JOHN L. LOMBARDI, CHUCHAWIN CHANGTONG
-
Patent number: 7794858Abstract: Provided are a phenylphenoxazine- or phenylphenothiazine-based compound and an organic electroluminescent device using the same. The phenylphenoxazine- or phenylphenothiazine-based compound is easily prepared, easily dissolved, and has excellent hole injection properties and excellent thermal stability. Accordingly, the compound is suitable for an organic layer of the organic electroluminescent device, specifically, a hole injection layer or a hole transport layer. In addition, the compound is suitable for an organic pigment or an electronic material, such as a nonlinear optical material.Type: GrantFiled: March 6, 2008Date of Patent: September 14, 2010Assignees: Samsung Electronics Co., Ltd., Samsung Mobile Display Co., Ltd.Inventors: Sang-hoon Park, O-hyun Kwon, Woon-jung Paek
-
Patent number: 7790881Abstract: This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7 diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiazinium compounds”) including Methylthioninium Chloride (MTC) (also known as Methylene Blue). In one embodiment, the method comprises the steps of, in order: nitrosylation (NOS); nitrosyl reduction (NR); thiosulfonic acid formation (TSAF); oxidative coupling (OC); Cr(VI) reduction (CR); isolation and purification of zwitterionic intermediate (IAPOZI); ring closure (RC); chloride salt formation (CSF); one of: sulphide treatment (ST); dimethyldithiocarbamate treatment (DT); carbonate treatment (CT); ethylenediaminetetraacetic acid treatment (EDTAT); organic extraction (OE); and recrystallisation (RX). The present invention also pertains to the resulting (high purity) compounds, compositions comprising them (e.g.Type: GrantFiled: September 21, 2005Date of Patent: September 7, 2010Assignee: Wista Laboratories Ltd.Inventors: John Mervyn David Storey, James Peter Sinclair, Colin Marshall, Han Wan Tan
-
Publication number: 20100204215Abstract: Novel 2,8-diaminophenothiazine compounds, a method for preparing the same, and uses of the novel 2,8-diaminophenothiazine compounds in the field of treating liquid or gaseous fluids, especially influents and industrial or domestic effluents.Type: ApplicationFiled: September 5, 2008Publication date: August 12, 2010Applicant: PHARMA HYDRO DEVELOPMENT - P.H.D.Inventors: Laurent Galey, Fabrice Peters, Xavier Ferry
-
Patent number: 7758861Abstract: The present invention discloses dye-sulfenate derivatives and their bioconjugates for dual phototherapy of tumors and other lesions. The compounds of the present invention may contain either a mixture of Type 1 and Type 2 agents or a single entity that integrates both units in the same molecules. The compounds are designed to produce both Type 1 and Type 2 phototherapeutic effect at once using dual wavelength light source that will produce singlet oxygen and free radicals at the lesion of interest.Type: GrantFiled: March 21, 2006Date of Patent: July 20, 2010Assignee: Mallinckrodt Inc.Inventors: Raghavan Rajagopalan, Samuel I. Achilefu, Joseph E. Bugaj, Richard D. Dorshow
-
Publication number: 20100137249Abstract: The present disclosure encompasses compounds and compositions that are useful as specific AI-2 antagonists for the control of bacterial quorum sensing. Although the AI-2 antagonists according to the present disclosure may not have bactericidal effect, their ability to attenuate virulence, drug resistance, and/or biofilm formation have therapeutic benefits. In addition, the AI-2 antagonists of the present disclosure can also be used as tools to probe bacterial AI-2 functions. The present disclosure also encompasses methods for inhibiting or attenuating microbial virulence, biofilm formation, and drug resistance. The methods are suitable for preventing bacteria from accruing and forming extensive biofilms that may be a health or hygiene hazard or a physical issue, such as in the blockage of water or fuel lines.Type: ApplicationFiled: June 6, 2008Publication date: June 3, 2010Inventors: Binghe Wang, Nanting Ni, Junfeng Wang, Chung-Dar Lu, Han-Ting Chou, Minyong Li, Shilong Zheng, Yunfeng Cheng, Hanjing Peng
-
Patent number: 7723515Abstract: A methylene blue—curcumin hybrid useful in treating Alzheimer's Disease.Type: GrantFiled: January 26, 2009Date of Patent: May 25, 2010Assignee: Codman & Shurtleff, Inc.Inventor: Thomas M. DiMauro
-
Patent number: 7704667Abstract: There are described novel rhodamine dye compounds and imaging members and imaging methods, including thermal imaging members and imaging methods, utilizing the compounds. The dye compounds exhibit a first color when in the crystalline form and a second color, different from the first color, when in the liquid, amorphous form.Type: GrantFiled: January 30, 2008Date of Patent: April 27, 2010Assignee: Zink Imaging, Inc.Inventors: Kap-Soo Cheon, Stephen J. Telfer, Michael P. Filosa, John L. Marshall, Fariza B. Hasan, David A. Skyler, John M. Hardin
-
Publication number: 20090291943Abstract: Process for preparing compounds of the diaminophenothiazinium type comprising a step for purification of derivatives (II). The products resulting from this process have a high degree of purity. Use of these compounds for the preparation of medicaments.Type: ApplicationFiled: July 12, 2007Publication date: November 26, 2009Inventors: Michel Feraud, Babak Sayah
-
Publication number: 20090209526Abstract: The invention relates generally to the use of diaminophenothiazine compounds to inhibit or reverse the aggregation of synuclein, and for their use in the manufacture of medicaments for this purpose (e.g. for the treatment of Parkinson's Disease). Also provided are related methods of detecting or labelling of aggregated synuclein.Type: ApplicationFiled: March 28, 2007Publication date: August 20, 2009Inventors: Claude Michel Wischik, Janet Elizabeth Rickard, Charles Robert Harrington, David Horsley
-
Publication number: 20090087916Abstract: The present invention provides a method of identifying a drug candidate capable of removing peptide, oligopeptide, polypeptide or protein from fibril or aggregate, which includes measuring, in the presence of a test compound, the concentration of a soluble peptide, a soluble oligopeptide, a soluble polypeptide or a soluble protein in an equilibrium state in a solvent. Moreover, the present invention provides a dissolution promoter to remove peptide, oligopeptide, polypeptide or protein from fibril or aggregate, which contains the compound obtained by the identification method as an active ingredient.Type: ApplicationFiled: March 30, 2005Publication date: April 2, 2009Applicant: AnGesMG, Inc.Inventors: Naoyuki Sato, Masayasu Okochi, Yoshiaki Taniyama, Toshio Ogihara, Ryuichi Morishita
-
Publication number: 20090088490Abstract: A simultaneous two-photon absorption three-dimensional recording material includes at least one kind of dye having at least one polymerizable group.Type: ApplicationFiled: September 26, 2008Publication date: April 2, 2009Applicant: FUJIFILM CORPORATIONInventors: Masaharu AKIBA, Hiroo TAKIZAWA
-
Publication number: 20090054419Abstract: This invention pertains generally to the field of phenothiazine compounds, and more particularly to certain stably reduced phenothiazine compounds, specifically, certain 3,7 diamino-10H-phenothiazine (DAPTZ) compounds of the following formula wherein: each of R1 and R9 is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R3NA and R3NB is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R7NA and R7NB is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of HX1 and HX2 is independently a protic acid; and pharmaceutically acceptable salts, solvates, and hydrates thereof. These compounds are useful as drugs, for example, in the treatment of tauopathies, such as Alzheimer's disease, and also as prodrugs for the corresponding oxidized thioninium drugs (for example, methythioninium chloride, MTC).Type: ApplicationFiled: March 28, 2007Publication date: February 26, 2009Inventors: Claude Michel Wischik, Janet Elizabeth Rickard, Charles Robert Harrington, David Horsley, John Mervyn David Storey, Colin Marshall, James Peter Sinclair, Thomas Craven Baddeley
-
Publication number: 20090026928Abstract: Provided are a phenylphenoxazine- or phenylphenothiazine-based compound and an organic electroluminescent device using the same. The phenylphenoxazine- or phenylphenothiazine-based compound is easily prepared, easily dissolved, and has excellent hole injection properties and excellent thermal stability. Accordingly, the compound is suitable for an organic layer of the organic electroluminescent device, specifically, a hole injection layer or a hole transport layer. In addition, the compound is suitable for an organic pigment or an electronic material, such as a nonlinear optical material.Type: ApplicationFiled: March 6, 2008Publication date: January 29, 2009Applicant: SAMSUNG ELECTRONICS CO., LTD.Inventors: Sang-hoon PARK, O-hyun KWON, Woon-jung PAEK
-
Publication number: 20080312219Abstract: The present invention relates to a phenothiazinium compound of Formula (I): wherein: A and B each independently is in which R? and R? each independently is a linear, branched or cyclic hydrocarbon group, or R? and R? together with the N atom to which they are attached form an optionally substituted 5-, 6- or 7-membered ring; and where XP? is a counteranion and P is 1, 2 or 3; except for the compounds in which A and B are both either —N(CH3)2 or —N(CH2CH3)2 for use in a treatment that requires removal, deactivation or killing of unwanted tissues or cells. The invention also relates to compositions comprising the compounds of Formula I, to selected compounds of Formula I, use of the compounds of Formula I as medicaments and as a PDT agent or a photodiagnostic agent, a conjugate or composite formed between a compound of Formula I and a polymer; and to a method for sterilising fluids in which the fluid is passed over the conjugate or composite whilst it is illuminated.Type: ApplicationFiled: May 12, 2008Publication date: December 18, 2008Applicant: PHOTOPHARMICA LIMITEDInventors: Stanley Beames Brown, Cassandra Claire O'Grady, John Griffiths, Kirste Joanne Mellish, Richard George Tunstall, David John Howard Roberts, David Ian Vernon
-
Patent number: 7407953Abstract: A phenothiazinium compound, compositions and medicaments for use in promoting wound healing and a method for promoting wound healing or cosmetic use by applying or administering a phenothiazinium compound of Formula (1) to a wound site or the skin, and optionally exposing the wound site or skin to light.Type: GrantFiled: March 20, 2007Date of Patent: August 5, 2008Assignee: Photopharmica LimitedInventors: Stanley Beames Brown, Cassandra Clare O'Grady
-
Patent number: 7282584Abstract: Composition comprising a polymerizable compound with at least one conjugated unsaturated group and methylene blue to prevent premature polymerization of the polymerizable compound. The methylene blue is present in a concentration of 10 to 5000 ppm.Type: GrantFiled: September 15, 2006Date of Patent: October 16, 2007Assignee: Straumann Holding AGInventor: Aaldert Molenberg
-
Patent number: 7253279Abstract: This invention relates to a method for inhibiting polymerization of (meth)acrylic acid and its esters using a polymerization inhibitor which comprises at least one reduced halide-content azine dye-based compound. A process for producing reduced halide-content azine dye-based compounds using ion exchange resin technology is also provided.Type: GrantFiled: April 5, 2007Date of Patent: August 7, 2007Assignee: Rohm and Haas CompanyInventors: Stephen Bass, Robert Michael Mason, Joy Lyndon Mendoza, Steven John Skoog, Mark T. Vandersall
-
Patent number: 7176308Abstract: Methods for the preparation of 7-(dipropylamino)pheno-thiazin-3-ylidene]-dipropylamine.Type: GrantFiled: November 17, 2003Date of Patent: February 13, 2007Assignee: Verification Technologies, Inc.Inventors: Rakesh Vig, Scott Gerger, Richard H. Selinfreund, Peter Miller, Mike Cunningham, Chris Phillips, Ewell Cook, Anthony A. Saglimbeni
-
Patent number: 7101997Abstract: A process for producing a phenothiazinium compound comprising the step of: reacting phenothiazine, in the presence of a halogen, with at least one amine selected from the group consisting of: wherein Z is CH2, O, S, SO2, NH, NCH3, NC2H5, NCH2CH2OH or NCOCH3, and R1 and R2 are each independently linear or branched CnH2nY.Type: GrantFiled: October 7, 2004Date of Patent: September 5, 2006Assignee: Honeywell International Inc.Inventors: Suzanne Wassmann-Wilken, Reinhard Knieps, Thomas Potrawa, Andreas Kanschik-Conradsen, Joachim Schulz, Christian Werner
-
Patent number: 6830743Abstract: Compounds having the structural formula (A) wherein X is hydrogen, methyl, or Y; Y is —NH—R or hydrogen; and R is methyl or formula (B) are useful as in vivo stains for the detection of dysplastic tissue.Type: GrantFiled: January 22, 2002Date of Patent: December 14, 2004Assignee: Zila Biotechnology, Inc.Inventor: Douglas D. Burkett
-
Patent number: 6800656Abstract: The present invention provides a compound of the formula and pharmaceutically acceptable salts having useful antiviral activity against viruses of the herpes family. Wherein: X=O, (CH2)m, S, SO, SO2, NH, NR8; Y=O, (CH2)m, S, SO, SO2, NH, NR8 or a chemical bond; Z=NH, O, NR8, S, SO, SO2; The remaining substituents are described in the specification.Type: GrantFiled: July 5, 2002Date of Patent: October 5, 2004Assignee: Warner Lambert CompanyInventors: Richard John Booth, Vara Prasad Venkata Nagendra Josyula, Annette Lynn Meyer, Bruce Allan Steinbaugh
-
Publication number: 20040167118Abstract: The invention relates to a compound represented by the following general formula (1) or its analogue, which selectively inhibit N-type calcium channels or its analogue, and to a method for treating pain etc.Type: ApplicationFiled: February 27, 2004Publication date: August 26, 2004Applicant: AJINOMOTO CO., INC.Inventors: Takashi Yamamoto, Seiji Niwa, Kayo Otani, Seiji Ohno, Hajime Koganei, Satoshi Iwayama, Akira Takahara, Yukitsugu Ono, Tomoko Takeda, Shinichi Fujita, Keiko Moki
-
Publication number: 20040147508Abstract: The present invention relates to a phenothiazinium compound of Formula (I): 1Type: ApplicationFiled: November 26, 2003Publication date: July 29, 2004Applicant: PHOTOPHARMICA LIMITEDInventors: Stanley Beames Brown, Cassandra Claire O'Grady, John Griffiths, Kirste Joanne Mellish, Richard George Tunstall, David John Howard Roberts, David Ian Vernon
-
Publication number: 20040121262Abstract: A copy-protected optical medium comprising transient optical state change security materials that demonstrating an optical state change when exposed to the wavelengths of from about about 770 nm to about 830 nm.Type: ApplicationFiled: September 26, 2003Publication date: June 24, 2004Inventors: Richard H. Selinfreund, Scott Gerger, Rakesh Vig, Junzhong Li
-
Patent number: 6747024Abstract: The present invention relates to new heterocyclic derivatives having an inhibitory activity on calpains and/or a trapping activity on reactive oxygen species, of formula in which A, X, Y, R1, R2 and Het represent variable groups. The invention also relates to their preparation methods, the pharmaceutical preparations containing them and their use for therapeutic purposes, in particular as inhibitors of calpains and/or traps of reactive oxygen species, selectively or non-selectively.Type: GrantFiled: April 30, 2002Date of Patent: June 8, 2004Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.)Inventors: Serge Auvin, Pierre-Etienne Chabrier de Lassauniere